Contemporary research identified that anti-PD1 immunotherapy can be potentiated in cases with the high PD-L1 expression in the tumor microenvironment,encompassing specific malignancies,such as HNSCC. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.